Rakovina Therapeutics

Rakovina Therapeutics

Biotechnology Research

Vancouver, British Columbia 683 followers

Utilizing Deep Docking™ AI, we target DNA-damage response (DDR) for oncology focused precision medicines. | TSXV: RKV

About us

We use cutting edge Deep Docking™ AI to target DNA-damage response (DDR) mechanisms and create innovative precision medicines with the potential to improve patient outcomes across multiple tumor types. DDR is a collection of processes that identify and correct DNA damage in our cells millions of times every day. Many cancers harbor a defect in natural DDR mechanisms that allow tumor cells to evade the human immune system and grow unchecked into life-threatening malignancies. TSXV: RKV

Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Vancouver, British Columbia
Type
Public Company
Founded
2020

Locations

  • Primary

    2201 - 8 Smithe Mews

    Vancouver, British Columbia V6B 0A5, CA

    Get directions

Employees at Rakovina Therapeutics

Updates

Similar pages

Browse jobs

Funding

Rakovina Therapeutics 3 total rounds

Last Round

Post IPO equity

US$ 1.7M

See more info on crunchbase